Peter Ordentlich
Oprichter bij SYNDAX PHARMACEUTICALS, INC.
Vermogen: 5 451 $ op 30-04-2024
Actieve functies van Peter Ordentlich
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
SYNDAX PHARMACEUTICALS, INC. | Hoofd Techniek/Wetenschap/O&O | 01-11-2013 | - |
Oprichter | 11-10-2005 | - |
Loopbaan van Peter Ordentlich
Eerdere bekende functies van Peter Ordentlich
Bedrijven | Functie | Begin | Einde |
---|---|---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Corporate Officer/Principal | - | - |
The Salk Institute for Biological Studies | Corporate Officer/Principal | - | - |
Opleiding van Peter Ordentlich
University of Pennsylvania | Doctorate Degree |
Statistieken
Internationaal
Verenigde Staten | 5 |
Operationeel
Corporate Officer/Principal | 2 |
Chief Tech/Sci/R&D Officer | 1 |
Founder | 1 |
Sectoraal
Consumer Services | 3 |
Health Technology | 2 |
Commercial Services | 2 |
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Verwante bedrijven
Beursgenoteerde bedrijven | 1 |
---|---|
SYNDAX PHARMACEUTICALS, INC. | Health Technology |
Bedrijven in privébezit | 1 |
---|---|
X-Ceptor Therapeutics, Inc.
X-Ceptor Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services X-Ceptor is a privately held biopharmaceutical company focusing on research in the rapidly developing field of orphan nuclear receptors that serve as the molecular targets for the discovery of novel small molecule pharmaceutical products for the treatment of human diseases. X-Ceptor has developed an integrated approach to drug discovery drawing from their in-house expertise in biology, chemistry and high-throughput screening. X-Ceptor's advantage lies in its understanding of orphan nuclear receptors and their signaling pathways, as well as its proprietary ability to employ these orphan nuclear receptors in transcriptional and biochemical based assays to discover novel therapeutic agents | Commercial Services |
- Beurs
- Insiders
- Peter Ordentlich
- Ervaring